Q2 2026 revenues rose 17% year-over-year to $4.29B, driven by Dupixent and Libtayo, while EYLEA sales declined due to biosimilar competition. Net income was $1.30B with EPS of $12.23. The company faces ongoing pricing, regulatory, and competitive pressures, but maintains a strong pipeline and robus…
Q2 2026 revenues rose 17% year-over-year to $4.29B, driven by Dupixent and Libtayo, while EYLEA sales declined due to biosimilar competition. Net income was $1.30B with EPS of $12.23. The company faces ongoing pricing, regulatory, and competitive pressures, but maintains a strong pipeline and robust cash position.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
